Aditxt (NASDAQ: ADTX) is a biotech innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system. The company today announced the formation of a U.S.-based subsidiary Adimune Inc. (“Adimune(TM)”) and its plans towards submission of a clinical trial application (“CTA”) for its immunotherapeutic technology drug candidate, ADI(TM)-100. The CTA application will request approval for Adimune to conduct the first-in-human study in psoriasis patients, beginning in the second half of 2023, with a second study also planned for type 1 diabetes. Joachim-Friedrich Kapp, M.D., Ph.D., a 30-year veteran of the pharmaceutical industry and former president of the therapeutics business unit at multinational pharmaceutical company Schering AG, will serve as chairman of the board and CEO of Adimune. “My vision for Adimune is to advance our program and effectively demonstrate that ADI technology is designed to restore immune health in patients with autoimmune diseases such as psoriasis and type 1 diabetes,” said Dr. Kapp. “We believe 2023 will be a pivotal year for us as we prepare and implement CTA approved clinical human trials featuring our drug candidate, ADI-100, which we believe to be extremely promising.”
To view the full press release, visit https://ibn.fm/k4IxX
About Aditxt Inc.
Aditxt is a biotech innovation company developing and commercializing technologies focused on monitoring and modulating the immune system. Aditxt’s immune monitoring technologies are designed to provide a personalized immune profile. Aditxt’s immune modulating technologies, currently preclinical, are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases and allergies. For more information, visit the company’s websites at www.Aditxt.com and www.AditxtScore.com.
NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
San Francisco, California
BioMedWire is part of the InvestorBrandNetwork